Atypical antipsychotics in ordinary clinical practice: A pharmaco- epidemiologic survey in a south London service

European Psychiatry

Volumn 15, Issue 3, 2000, Pages 220-226

  Frangou, S ^a   Lewis, M ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Antipsychotics; Pharmaco epidemiology; Prescribing; Schizophrenia

Indexed keywords

ANTIDEPRESSANT AGENT; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; SERTINDOLE; TRIFLUOPERAZINE;

ADULT; ARTICLE; COMBINATION CHEMOTHERAPY; DRUG RESPONSE; FEMALE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PHARMACOEPIDEMIOLOGY; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; SCHIZOPHRENIA; SEX DIFFERENCE; SUICIDE; UNITED KINGDOM;

EID: 0034076644     PISSN: 09249338     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-9338(00)00222-4     Document Type: Article

References (26)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. 1994;APA, Washington DC.
2. Baldessarini R.J., Kando J.C., Centorrino F. Hospital use of antipsychotic agents in 1989 and 1993: stable dosing with decreased length of stay. Am J Psychiatry. 152:1995;1038-1044.
3. Drug Information Quarterly. Bethlem and Maudsley NHS Trust Drugs and Therapeutics Committee. 1998;Maudsley, London.
4. Bondolfi G., Dufour H., Patris M., May J.P., Billeter U., Eap C.B., et al. Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. The Risperidone Study Group. Am J Psychiatry. 155:1998;499-504.
5. Conley R.R., Tamminga C.A., Bartko J.J., Richardson C., Peszke M., Lingle J., et al. Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia. Am J Psychiatry. 155:1998;914-920.
6. Farde L., Hall H., Ehrin E., Sedvall G. Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET. Science. 231:1989;258-261.
7. Farde L., Nordstrom A.L., Wiesel F.A., Pauli S., Halldin C., Sedvall G. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: relation to extrapyramidal side effects. Arch Gen Psychiatry. 49:1992;538-544.
8. Flynn S.W., Macewan G.W., Altman S., Kopala L.C., Fredrikson D.H., Smith G.N., et al. An open comparison of clozapine and risperidone in treatment-resistant schizophrenia. Pharmacopsychiatry. 31:1998;25-29.
9. Frangou S., Murray R.M. Antipsychotic drugs. Schizophrenia. 1996;34-46 Martin Dunitz, London.
10. Galletly C.A. Antipsychotic drug doses in a schizophrenia inpatient unit. Aust N Z J Psychiatry. 26:1992;574-576.
11. Heinrich K., Klieser E., Lehmann E., Kinzler E., Hruschka H. Risperidone versus clozapine in the treatment of schizophrenic patients with acute symptoms: a double blind, randomized clinical trial. Prog Neuropsychopharmacol Biol Psychiatry. 18:1994;129-137.
12. Henderson D.C., Goff D.C. Risperidone as an adjunct to clozapine therapy in chronic schizophrenics. J Clin Psychiatry. 57:1996;395-397.
13. Jeffreys S.E., Harvey C.A., Mc Naught A.S., Quayle A.S., King M.B., Bird A.S. The Hampstead Schizophrenia Survey 1991. I: Prevalence and service use comparisons in an inner London health authority, 1986-1991. Br J Psychiatry. 170:1997;301-306.
14. Kane J., Honigfeld G., Singer J., Meltzer H. Clozapine for the treatment resistant schizophrenic: a double blind comparison with chlorpromazine. Arch Gen Psychiatry. 45:1988;789-796.
15. Leucht S., Pitschel-Walz G., Abraham D., Kissling W. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr Res. 35:1999;51-68.
16. Lindenmayer J.P., Iskander A., Park M., Apergi F.S., Czobor P., Smith R., et al. Clinical and neurocognitive effects of clozapine and risperidone in treatment-refractory schizophrenic patients: a prospective study. J Clin Psychiatry. 59:1998;521-527.
17. Martin J., Gomez J.C., Garcia-Bernardo E., Cuesta M., Alvarez E., Gurpegui M. Olanzapine in treatment-refractory schizophrenia: results of an open-label study. The Spanish Group for the Study of Olanzapine in Treatment-Refractory Schizophrenia. Clin Psychiatry. 58:1997;479-483.
18. Meltzer H.Y., Burnett S., Bastani B., Ramirez L.F. Effect of six months of clozapine treatment on the quality of life of chronic schizophrenic patients. Hosp Community Psychiatry. 41:1990;892-897.
19. Peralta V., Cuesta M.J., Caro F., Martinez-Larrea A. Neuroleptic dose and schizophrenic symptoms. A survey of prescribing practices. Acta Psychiatr Scand. 90:1994;354-357.
20. Reardon G.T., Rifkin A., Schwartz A., Myerson A., Siris S.G. Changing patterns of neuroleptic dosage over a decade. Am J Psychiatry. 146:1989;726-729.
21. Remington G.J., Prendergast P., Bezchlibnyk-Butler K.Z. Neuroleptic dosing in chronic schizophrenia: a 10-year follow-up. Can J Psychiatry. 42:1997;53-57.
22. Shiloh R., Zemishlany Z., Aizenberg D., Radwan M., Schwartz B., Dorfman-Etrog P., et al. Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. A double-blind, placebo-controlled study. Br J Psychiatry. 171:1997;569-573.
23. Smith R.C., Chua J.W., Lipetsker B., Bhattacharyya A. Efficacy of risperidone in reducing positive and negative symptoms in medication-refractory schizophrenia: an open prospective study. J Clin Psychiatry. 5:1996;460-466.
24. Taylor D., Kerwin R. Maudsley prescribing guidelines. 1999;Maudsley, London.
25. Zimbroff D.L., Kane J.M., Tamminga C.A., Daniel D.G., Mack R.J., Wozniak P.J., et al. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group. Am J Psychiatry. 154:1997;782-791.
26. Zito J.M., Craig T.J., Wanderling J., Siegel C. Pharmaco-epidemiology in 136 hospitalized schizophrenic patients. Am J Psychiatry. 144:1987;778-782.